Recent Updates
Recently added Catalysts
IVVD Positive Sentiment

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Key Takeaway: Invivyd, Inc. will hold a conference call on March 5, 2026, to discuss its fourth quarter and full-year 2025 financial results, along with a corporate update. The call is scheduled for 8:30 a.m. ET, and interested parties can join via a live webcast. A recording will be available afterward on the company's investor relations website.
Price reaction · baseline $1.72 (2026-03-02 close) · hit pre-market · 2 other IVVD headline(s) in the window, move may be shared
day 0 close · peak
-5.8%
day 1
-0.6%
day 3
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Invivyd is hosting a conference call to discuss financial results.
  • The company is focused on serious viral infectious diseases.
  • Invivyd has received emergency use authorization for a monoclonal antibody.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~11 mo
Medium dilution risk
Lead asset
VYD2311-SD
Phase 3 · COVID-19

Full Press Release Details

NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update.
Interested parties may join the live webcast by visiting thislink. Analysts wishing to participate in the question-and-answer session should use thislink. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company’s investor relations website shortly after the event.

About Invivyd

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

Contacts:Media Relations(781) 208-0160media@invivyd.com

Investor Relations(781) 208-1747investors@invivyd.com

Frequently Asked Questions

When is Invivyd's conference call for financial results?

The conference call is scheduled for March 5, 2026, at 8:30 a.m. ET.

How can I join the Invivyd conference call?

Interested parties can join the live webcast by visiting the provided link.

What will Invivyd discuss during the call?

Invivyd will discuss its fourth quarter and full-year 2025 financial results.

Will a recording of the conference call be available?

Yes, a recording will be available on the company's investor relations website after the event.

Last updated: Mar 3, 2026